CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2015 Gastrointestinal Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer
Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer
Dr. Zafar on Low BMI Impact on Colorectal Cancer Survival
Oncology Conference Articles
Multitargeted Drug Slows CRC as Third-Line Therapy
Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.
Monocyte-Targeting Agent Active in Locally Advanced Pancreatic Cancer
Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.
Lanreotide Effective in Pancreatic NET Subgroup
Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.
Ramucirumab Improves Survival in HCC Subgroup
An analysis of patients with advanced hepatocellular carcinoma and elevated Î±-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.
Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer
Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.
Polymorphisms May Offer Clues to Treatment Outcomes in HCC
Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.
Adjusted Nab-Paclitaxel/Gemcitabine Regimen Less Toxic in Pancreatic Cancer
Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.
MET Inhibition Shows Some Promise in Advanced Gastroesophageal Cancer
Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.
Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer
Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.
FOLFOXIRI Plus Bevacizumab Superior as Frontline mCRC Regimen
Intensifying the chemotherapy component of a standard first-line bevacizumab-containing regimen reduced the risk of death by about 20% and doubled the 5-year overall survival (OS) rate among patients with metastatic colorectal cancer (mCRC).
Surveillance Could Be a Viable Option for Select Patients With Rectal Cancer
A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.
Higher Vitamin D Levels Improve Survival for Patients With mCRC
Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.
Ramucirumab Improves Survival in Second-Line mCRC
Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
Targeting BCL-2 in Hematologic Malignancies
Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma
Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.